Skip to content

News & Events

Academic Breast Cancer Consortium (ABRCC)​

What’s New in Breast Cancer Research and Treatment?
Criterium's Academic Breast Cancer Consortium (ABRCC) is comprised of 15 renowned academic and community sites in North America, conducting translational research in Breast Cancer studies for major pharmaceutical companies who are working on the most current clinical trials for advanced treatments of breast cancer. While 2020 was a year dominated by COVID-19 news and tragedy, breast cancer research and breakthroughs can't wait for COVID to "go away" – and research in this area continues on full-speed. Our ABRCC researchers reflect on 2020 and look ahead to 2021 with renewed hope.
Following NCCN Guidelines for Metastatic Breast Cancer Results in Lower Costs for Patients
Research from the O’Neal Comprehensive Cancer Center at UAB finds patients treated outside of NCCN Guidelines recommendations had significantly higher direct costs. A new study from the O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham (UAB), published in the October 2019 issue of JNCCN—Journal of the National Comprehensive Cancer
CRITERIUM, Inc. CRO’s Two Consortia Directors Receive Promotions, Tenure at UCD
Criterium, Inc., a full-service CRO is pleased to announce the promotions of our two newest consortia directors, Drs D. Ross Camidge and Peter Kabos, both from the University of Colorado. Dr Camidge, Director for the ATOMIC Consortia for Thoracic and Lung Cancers, was recently promoted from his current position of Associate Professor, Division of Medical Oncology to "Professor with Tenure". Dr Kabos, Director for the ABRCC Consortia for Breast Cancer, was recently promoted from his current position of Assistant Professor, Division of Medical Oncology to "Associate Professor".
CRITERIUM, Inc. Announces the Formation of Two New Oncology Consortia
Criterium, Inc., a full service global CRO is pleased to announce the formation of its two new oncology consortia: ATOMIC (The Academic Thoracic Oncology Medical Investigator’s Consortium) focusing on Thoracic and Lung Cancers, and ABRCC (The Academic Breast Cancer Consortium), dedicated to Breast Cancer research.
CRITERIUM, Inc. CRO’s ABRCC Presents Poster at SABCS 2017 for “TULiP” Trial
Elena Shagisultanova, MD, PhD, Assistant Professor at the University of Colorado Denver Cancer Center and Lead Principal Investigator of the TULiP trial presented a trials-in-progress poster summarizing the study design for the ongoing trial in patients with hormone receptor positive and HER2-positive (HR+/HER2+) metastatic breast cancer.